Table 2.
Menopausal women’s climacteric symptoms scores in the two groups over time
| Time | Melatonin group* (CI 95%) † | Placebo group (CI 95%) † |
|---|---|---|
| Before the intervention n1:120, n2:120†† | 35.22+10.50b,c,d**(33.12-37.33) | 35.68+9.93b,c,d (33.72-37.64) |
| 1 month after the intervention n1:115, n2:116 | 25.43+11.11a,c,d (23.20-27.66) | 29.33+10.35a,c,d (27.28-31.37) |
| 2 months after the intervention n1:109, n2:109 | 21.16+10.54a,b,d (19.05-23.28) | 25.81+11.10a,b (23.62-28.00) |
| 3 months after the intervention n1:98, n2:101 | 17.09+10.17a,b,c (15.05-19.13) | 24.42+11.01a,b (22.24-26.59) |
*: values are given as mean± standard deviation. Repeated Measure ANOVA test and then Sidak Post hoc showed that a significant difference was found in the melatonin group’s climacteric symptoms score 3 months after the intervention (P=0.005).
**: the two groups were similar regarding the Greene Climacteric Scale before the intervention (P>0.05)./ a: significant difference compared to before the intervention/b: significant difference compared to 1 month after the intervention/c: significant difference compared to 2 months after the intervention/d: significant difference compared to 3 months after the/†: Confedence interval 95% / ††:n1 number of women in melatonin group, n2: number of women in placebo group